Detalhe da pesquisa
1.
Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.
Int J Cancer
; 150(7): 1184-1197, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34913485
2.
Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.
Blood
; 136(7): 871-884, 2020 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32391874
3.
Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells.
Blood Adv
; 8(6): 1345-1358, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38190613
4.
Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.
Cancer Res Commun
; 3(2): 297-308, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36860654
5.
A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation.
Cancers (Basel)
; 15(20)2023 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37894456
6.
Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.
Blood Adv
; 7(8): 1545-1559, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36516085
7.
Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.
Cancer Lett
; 526: 273-283, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34875342
8.
Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects.
Mol Cancer Ther
; 20(8): 1412-1421, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34045225